Neuropharm (NHP)

Find Your Broker
Company name:Neuropharm
EPIC:NHP (delisted)Trading Currency:GBX
Market Sector:AIMISIN:GB00B1NPJJ01
Market Segment:AIMShare Type:DE
Industry Sector:REAL ESTATE
 Price Price Change [%] Bid Offer Open High Low Volume
 - [] - - - - - -
 Market Cap. [m] Shares In Issue [m] Beta EPS DPS PE Ratio Yield 52-Wks-Range
 - - - 15.50 300.00 - - -

Neuropharm Key Figures

KEY FIGURES at Previous Day's Close - Not Available

Neuropharm Balance Sheet


Share Price Performance

Sorry No Data Available

Share Price Chart (5 years)

Neuropharm Historic Returns

Sorry No Data Available

Neuropharm Key Management Ratios

Neuropharm Investment Ratios

(Market value analysis) at previous day's close
PQ Ratio- 
PE Ratio- 
Tobin's Q Ratio - 
Tobin's Q Ratio (excl. intangibles)- 
Dividend Yield-%
Market-to-Book Ratio- 
Price-to-Pre-Tax Profit PS- 
Price-to-Retained Profit PS- 
Price-to-Cash Flow PS- 
Price-to-Sales PS- 
Price-to-Net Tangible Asset Value PS- 
Price-to-Cash PS- 
Net Working Capital PS- 
Price Pct to Working Capital PS-%
Earnings Yield-%
Average PE9.67 
Years in average4 
PE to PE average-%

Neuropharm Financial Ratios

(Leverage Ratios)
Debt Ratio50.00%
Debt-to-Equity Ratio1.00 
Debt-to-Equity Ratio (excl. Intgbl)1.02 
Debt-to-Equity Market Value- 
Net Gearing48.49%
Net Gearing (excl. Intangibles)48.89%
Gross Gearing57.29%
Gross Gearing (excl. Intangibles)57.77%
Gearing Under 1 Year14.59%
Gearing Under 1 Year (excl. Intgbl)14.71%
(Liquidity Ratios)
Net Working Capital to Total Assets1.31%
Current Ratio1.09 
Quick Ratio (Acid Test)1.09 
Liquidity Ratio0.60 
Cash & Equiv/Current Assets55.31%
(Solvency Ratios)
Enterprise Value79.38m
CFO/Attributable Profit2.33 
Total Debt/Equity Market Value- 
Total Debt/Sales0.68 
Total Debt/Pre-Tax Profit3.77 
Total Debt134.15m
Total Debt/Net Current Assets42.81%
(Dodds - Graham Ratios)
3 yr Compound Earnings Growth15.35%
5 yr Compound Earnings Growth-%
10 yr Compound Earnings Growth-%
Earn drops > 5% in 10yrs1 
Beta (60-Mnth)Beta (36-Mnth)
Sorry No Data AvailableSorry No Data Available

Neuropharm Operating Ratios

(Profitability Ratios)
Return On Capital Employed (ROCE)17.81%
Return On Assets (ROA)13.15%
Net Profit Margin16.07%
Assets Turnover0.82 
Return On Equity (ROE)31.82%
Return On Investment (ROI)15.35%
Dividend Payout Ratio1,935.48%
Plowback Ratio-1,835.48%
Growth from Plowback Ratio-584.09%
Net Income Of Revenues12.94%
(Asset Utilisation Multiples)
Shareholders Equity Turnover1.98 
Fixed Assets Turnover0.98 
Current Assets Turnover4.95 
Net Working Capital Turnover 
Inventory Turnover170.15 
(Other Operating Ratios)
Total Assets-to-Sales1.22 
Debt Collection Period33.10Days

Neuropharm Dividends

Announcement DateTypeCurr.Dividend AmountPeriod StartPeriod EndEx DateRecord DatePayment DateTotal Dividend Amount
08 Dec 2004FinalGBP-30/09/200330/09/2004---3.00
28 May 2004InterimGBP3.0001/10/200331/03/200409/06/200411/06/200414/07/2004-
11 Dec 2003FinalGBP2.2530/09/200230/09/200304/02/200406/02/200403/03/20043.00
03 Jun 2003InterimGBP0.7530/09/200230/09/200311/06/200313/06/200314/07/2003-
09 Dec 1999FinalGBP3.2030/09/199830/09/199904/01/200010/01/200025/01/200011.60
08 Sep 1999QuarterlyGBP3.0030/09/199830/09/199920/09/199924/09/199908/10/1999-
03 Jun 1999QuarterlyGBP2.8030/09/199830/09/199928/06/199902/07/199909/07/1999-
03 Mar 1999QuarterlyGBP2.6030/09/199830/09/199915/03/199919/03/199909/04/1999-
25 Nov 1998FinalGBP2.4030/09/199730/09/199807/12/199811/12/199809/04/19998.40

Neuropharm Fundamentals

 30 Sep 2001 (GBP)30 Sep 2002 (GBP)30 Sep 2003 (GBP)30 Sep 2004 (GBP)
pre tax profit10.0313.08%16.3713.00%24.7614.40%35.6217.99%m
attributable profit12.4316.22%16.8813.40%25.3114.73%31.8216.07%m
retained profit12.4316.22%16.8813.40%19.2211.18%25.6312.94%m
eps - basic (p)8.10 10.10 12.60 15.50 
eps - diluted (p)8.10 9.90 12.20 15.10 
dividends per share- - 3.00 3.00 

Neuropharm Balance Sheet

 30 Sep 2001 (GBP)30 Sep 2002 (GBP)30 Sep 2003 (GBP)30 Sep 2004 (GBP)
 30 Sep 2001 (GBP)30 Sep 2002 (GBP)30 Sep 2003 (GBP)30 Sep 2004 (GBP)
fixed assets fixed assets100.0043.72%100.0041.63%100.0040.86%100.0041.80%m
intangibles intangibles0.960.42%2.170.90%2.050.84%1.940.81%m
fixed investments fixed investments100.0043.72%100.0041.63%100.0040.86%100.0041.80%m
current assets - other current assets - other--%--%--%--%m
stocks stocks2.701.18%2.971.24%2.330.95%--%m
debtors debtors8.043.51%14.886.19%19.267.87%16.666.97%m
cash & securities cash & securities17.057.45%20.218.41%21.108.62%20.628.62%m
creditors - short creditors - short27.3111.94%25.5610.64%35.1914.38%34.1514.28%m
creditors - long creditors - long100.0043.72%100.0041.63%100.0040.86%100.0041.80%m
creditors - other creditors - other--%--%--%--%m
subordinated loans subordinated loans--%--%--%--%m
insurance funds insurance funds--%--%--%--%m
ord cap, reserves ord cap, reserves100.0043.72%100.0041.63%100.0040.86%100.0041.80%m
prefs, minorities prefs, minorities--%--%--%--%m
NAV Basic65.50 103.40 157.60 242.70 
NAV Diluted65.50 103.40 151.80 235.50 

Neuropharm Cash Flow Statement

30 Sep 2001 (GBP)30 Sep 2002 (GBP)30 Sep 2003 (GBP)30 Sep 2004 (GBP)
Operating CF51.7957.8764.2874.20m
Pre-Financing CF46.579.6615.9722.17m
Retained CF2.50-2.30-2.570.02m

Neuropharm Brokers

Broker infomation is not available for this class of stock.
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:gb D:20190120 23:28:55